Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.
about
Adherence to antiretroviral therapy: merging the clinical and social course of AIDS.The Need for Pediatric Formulations to Treat Children with HIVComputer-based HIV adherence promotion interventions: a systematic review: Translation Behavioral MedicineModeling antiretroviral drug responses for HIV-1 infected patients using differential equation modelsBarriers and facilitators of interventions for improving antiretroviral therapy adherence: a systematic review of global qualitative evidenceA randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomesLong-term efficacy of first line antiretroviral therapy in Indian HIV-1 infected patients: a longitudinal cohort studyAdherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort StudyHIV drug resistance early warning indicators in namibia with updated World Health Organization guidanceDifferent frequencies of drug resistance mutations among HIV-1 subtypes circulating in China: a comprehensive studyMonitoring HIV Drug Resistance Early Warning Indicators in Cameroon: A Study Following the Revised World Health Organization RecommendationsEarly HAART Initiation May Not Reduce Actual Reproduction Number and Prevalence of MSM Infection: Perspectives from Coupled within- and between-Host Modelling Studies of Chinese MSM PopulationsHow Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health ImpactAssessment of the World Health Organization's HIV Drug Resistance Early Warning Indicators in Main and Decentralized Outreach Antiretroviral Therapy Sites in NamibiaPreparing for highly active antiretroviral therapy rollout in rural South Africa: an assessment using the information, motivation, and behavioral skills model.Potential Impact of Integrating HIV Surveillance and Clinic Data on Retention-in-Care Estimates and Re-Engagement EffortsLack of association between retrospectively collected pharmacy refill data and electronic drug monitoring of antiretroviral adherence.Understanding the facilitators and barriers of antiretroviral adherence in Peru: a qualitative study.The cost-effectiveness of directly observed highly-active antiretroviral therapy in the third trimester in HIV-infected pregnant women.Factors associated with suboptimal adherence to antiretroviral therapy in Asia.Knowledge and adherence to antiretroviral therapy among adult people living with HIV/AIDS treated in the health care centers of the association "Espoir Vie Togo" in Togo, West Africa.Developing useful highly active antiretroviral therapy adherence measures for India: the Prerana study.Magnitude and determinants of nonadherence and nonreadiness to highly active antiretroviral therapy among people living with HIV/AIDS in Northwest Ethiopia: a cross-sectional study.Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro, 1997-2011.Factors associated with lack of antiretroviral adherence among adolescents in a reference centre in Rio de Janeiro, Brazil.A comparison of adherence assessment methods utilized in the United States: perspectives of researchers, HIV-infected children, and their caregivers.Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulationEnd of the debate about antiretroviral treatment initiation.Impact of HIV-specialized pharmacies on adherence and persistence with antiretroviral therapy.Antiviral drug resistance as an adaptive processAdherence to highly active antiretroviral treatment in HIV-infected Rwandan women.Relationship of injection drug use, antiretroviral therapy resistance, and genetic diversity in the HIV-1 pol geneDelivery of HIV care during the 2007 post-election crisis in Kenya: a case study analyzing the response of the Academic Model Providing Access to Healthcare (AMPATH) programRelationship between viral load and self-report measures of medication adherence among youth with perinatal HIV infection.Determinants of antiretroviral therapy adherence in northern Tanzania: a comprehensive picture from the patient perspective.What is a missed dose? Implications for construct validity and patient adherenceMonitoring HIV treatment in developing countries.The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa.Measuring adherence to antiretroviral therapy in children and adolescents in western Kenya.Pediatric Human Immunodeficiency Virus Continuum of Care: A Concise Review of Evidence-Based Practice.
P2860
Q24810599-F4D61009-DE27-4BE6-BF0A-94F43CAA6743Q26740369-4988B64C-85C0-4D78-972E-EC5101F57BCEQ26795553-DB98E30E-A69B-43F9-8F64-203E6467A0CCQ27015861-D47CB276-4FF0-4011-80E1-C2EAC38E27C3Q28074440-4EF61477-0F0F-4A41-B916-777AB9F67045Q28477310-ADFD6A54-1EA9-4C1D-AD62-E5862BFFD2B6Q28485373-C0D6937F-A66F-4604-BBC2-4ACBE52E9A1EQ28534423-21159474-4042-4E33-9532-25AFCC175044Q28540264-9442CE42-7227-4976-B113-D6A107D5F2E6Q28541365-02F8C250-33C5-4563-8B97-0598CFE889D8Q28548432-453718FB-D0D4-4C71-B49A-F6BC0CE7F32AQ28550445-C097547A-139C-4F27-A155-8F5AE92597FBQ28552455-E7F93662-2A67-4BB9-8700-D00DC6A270DAQ28554721-6350480B-ED3F-4CE0-B98B-EE0424A38A76Q30227266-99E631E9-32A4-4198-B208-31FF8EB99500Q31128135-35394463-FF7C-4D88-9854-C0A829F31017Q33393729-4D2DBDB6-48BA-422F-AB0B-FAF9950453F3Q33523621-28C06715-5A7B-4209-837D-A5D8336409BDQ33559823-2FD338A1-263D-4C2B-B6BE-AF1FA216BD37Q33626312-8580ADE7-497B-44F7-A87E-AE21146E8748Q33694858-3AB33FFE-D5EC-4D87-80A2-627E819E1674Q33699710-A443E85B-C9B5-4A9C-8426-4205F51B0B40Q33753410-D4AE3FC1-66A5-4860-910C-5A38CC3845EEQ33793720-4777F2D8-5814-4F7F-9B30-81ED953A1922Q33801756-C07F8E21-A4B9-408C-98EB-EA99B96A2A92Q33810883-B44157E1-6D96-4DC6-92CC-F8DA1887536AQ33826308-6BB4985A-60FF-4167-8073-54FEDFD80639Q33855047-ADEBAE34-DACD-48BC-9D0F-2D63D1C9B047Q33869982-3975674E-F9B9-4F03-A839-B65C657BDA04Q33878407-380FA713-E85F-4049-9B73-43D5D455D555Q34082897-202EF7E9-419A-4291-AAE3-AECF28D3EEDDQ34118276-F2E647EE-6FE9-48BF-92F9-693EBE3B885DQ34250217-BB93B78E-C6A4-4F3A-9978-82A40D4B2E1DQ34307909-40C41126-C421-440F-9994-3C30559CF040Q34398331-5B32B226-56F6-4BEE-820E-A5CA6581609FQ34427759-60AE60A4-2B79-4866-890A-A0F9FC01F70DQ34441436-3B143EC9-6BB9-4531-8E5D-4FB75D2715DBQ34451025-F2F17C62-74C7-486A-B869-E62A091DA176Q34577449-35096849-1CC7-4615-A18E-CFF7D2A0898BQ34682648-02525FA2-C265-451F-A69A-29FD179D92C6
P2860
Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Association between adherence ...... iciency virus drug resistance.
@en
Association between adherence ...... iciency virus drug resistance.
@nl
type
label
Association between adherence ...... iciency virus drug resistance.
@en
Association between adherence ...... iciency virus drug resistance.
@nl
prefLabel
Association between adherence ...... iciency virus drug resistance.
@en
Association between adherence ...... iciency virus drug resistance.
@nl
P2093
P2860
P356
P1476
Association between adherence ...... iciency virus drug resistance.
@en
P2093
Ajay K Sethi
Joel E Gallant
Richard D Moore
P2860
P304
P356
10.1086/378301
P407
P577
2003-09-19T00:00:00Z